Magenta Medical Revenue and Competitors
Estimated Revenue & Valuation
- Magenta Medical's estimated annual revenue is currently $26.4M per year.
- Magenta Medical's estimated revenue per employee is $251,000
Employee Data
- Magenta Medical has 105 Employees.
- Magenta Medical grew their employee count by 25% last year.
Magenta Medical's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Operations | Reveal Email/Phone |
2 | Director Product Management | Reveal Email/Phone |
3 | Director QA | Reveal Email/Phone |
4 | Director QA | Reveal Email/Phone |
5 | Senior Director Clinical Affairs | Reveal Email/Phone |
6 | Director Engineering at Magenta Medical | Reveal Email/Phone |
7 | Director Product Management | Reveal Email/Phone |
8 | Quality Assurance Manager | Reveal Email/Phone |
9 | R&D Manager | Reveal Email/Phone |
10 | Supply Chain Manager | Reveal Email/Phone |
Magenta Medical Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $6.1M | 49 | -18% | $10M | N/A |
#2 | $30.4M | 121 | 29% | N/A | N/A |
#3 | $139.8M | 913 | -3% | $200K | N/A |
#4 | $84.1M | 0 | N/A | $1.2M | N/A |
#5 | $43.4M | 173 | 30% | N/A | N/A |
#6 | $64.5M | 257 | 12% | N/A | N/A |
#7 | $64.3M | 205 | 26% | $129.6M | N/A |
#8 | $19.6M | 78 | -7% | N/A | N/A |
#9 | $65.8M | 262 | 7% | N/A | N/A |
#10 | $73.7M | 235 | 20% | $115.5M | N/A |
What Is Magenta Medical?
Magenta Medical has developed a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF). Its novel therapeutic principle is aimed at addressing a pathophysiological core element of acute heart failure - renal venous congestion and its deleterious effects on renal and cardiac function.
keywords:N/A
N/A
Total Funding
105
Number of Employees
$26.4M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Magenta Medical News
2022-04-20 - GV, Sanofi drive British biotech OMass to $100M series B ...
Tirzepatide is the first investigational medicine to deliver more than 20% ... Magenta Therapeutics: Magenta is saying farewell to 14% of its staff as the...
2022-04-06 - UPDATE: Magenta cuts 14% of staff, trims R&D amid ...
Magenta Therapeutics is trimming around the edges, cutting 14% of staff and axing ... Nektar's Chief Medical officer Dimitry Nuyten, Ph.D.,...
Other Companies in Kadima
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $59.3M | 327 | 41% | N/A |